ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2472

A Randomized, Multicentre, Double Blind, Placebo-Controlled Trial of Anti TNF Alpha (adalimumab) in Refractory Hand Osteoarthritis: The Dora Study

Xavier Chevalier1, Philippe Ravaud2, Emmanuel Maheu3, Gabriel Baron4, Amandine Rialland5, Philippe Vergnaud6, Christian Roux7, Yves Maugars8, Denis Mulleman9, Bernard Combe10, Daniel Wendling11, Pierre Laforgue12, Damien Loeuille13, Violaine Foltz14 and Pascal Richette15, 1Department of Rheumatology Hopital Henri Mondor, Créteil, France, 2Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 3Rheumatology, AP-HP, St Antoine Hospital, Paris, France, 4Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, 5Unité de recherche clinique Henri Mondor, Créteil, France, 6CCRB Synarc Lyon, Lyon, France, 7Rheuamtology, CHU L' Archet University Nice, Nice, France, 8Rheumatology, Nantes University Hospital, Nantes, France, 9CHU Trousseau Tours, Tours, France, 10CHU Lapeyronie, Montpellier, France, 11Service de Rhumatologie, Minjoz University Hospital, Besancon, France, 12CHU la conception Marseille, Marseille, France, 13Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, 14APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, 15Lariboisière Hospital, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anti TNF, Hand and Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Hand osteoarthritis (HOA) is a frequent painful polyarticular disease which often does not respond to any classical therapeutics. TNF a is involved in the osteoarthritic process both in disease progression and in pain perception. 

objective: To evaluate TNF blockers in patients with painful OA refractory to analgesics and NSAIDs.

Methods:

The digital osteoarthritis in refractory hand OA study (DORA), is a phase 3 randomized superiority, double-blind (patients and assessors of outcomes), parallel, placebo controlled, 26 weeks, multicenter trial (conducted in 16 French clinical sites), using TNF blocker adalimumab (2 sub cutaneous injections at week 0 and week 2). Patients meeting the American College of Rheumatology criteria for hand OA with pain above 40 mm on a 100 mm visual analogue scale (VAS), involving at least 3 painful interphalangeal joints and at least 3 OA joints at Kellgren Lawrence (KL) grade > 2 on a recent radiograph, who did not respond to analgesics and NSAIDs, were recruited. Randomization and allocation to trial group were carried out by a central computer system. The primary endpoint was change in pain score after 6 weeks.  Secondary outcomes at 6 weeks were change in the number of spontaneous painful joints, in number of painful joints on pressure, in number of swollen joints, in morning stiffness, in patient’ and practitioner’ global assessments, in functional index for hand OA (FIHOA) and Cochin hand functional index.  Consumption of analgesics was recorded (acetaminophen up to 3g/D was the only rescue medication allowed until week 6). Serum markers (COMP, PIIANP, HA, usCRP, cytokines level of TNF a, IL-6, IL-1) and urine level of CTX-II (corrected by creatinine) were measured at W0 and W6.

Results:

On the 99 patients selected, 85 were randomized (42 in the placebo group, 41 in the adalimumab group). 35 patients in the placebo group and 38 in the adalimumab group received the two injections. 78 patients with at least one injection were analyzed (37 placebo and 41 adalimumab) (mITT). Mean (SD) age was 62.5 (6.9), 85 % of women, mean (SD) level of pain was 65.4 (12.9) mm; mean (SD) number of painful IP joints: 11 (6), mean number of joints with clinical synovitis was 5.9(4.4), mean FIHOA score 15.6 (6.3). The difference in the mean change in pain score on VAS (0-100 mm) over 6 weeks between adalimumab and placebo (primary end point) was: -2.5 mm (95% CI, -14.0 to 9.0), p: 0.67, non significant. No statistically significant differences were found for any of the secondary outcomes, except for a decrease in the number of swollen joints between week 0 and week 26 which favoured adalimumab group: mean difference: -1.9 (95% CI, -3.2 to – 0.6), p: 0.006. Analgesics use was similar between groups. There were no safety concerns. There was none variations of any biological markers between the 2 groups. TNF alpha serum level was not correlated with clinical outcome in the group of patients treated with adalimumab.

Conclusion:

In a group of patients with refractory hand OA, TNFa blockers (adalimumab, 2 sc injections) failed to demonstrate any clinical improvement.

Trial registrationclinicaltrials.gov Identifier: NCT00597623

Academic study sponsored by APHP clinical Research; supported by Osteoarthritis group of the French Society


Disclosure:

X. Chevalier,
None;

P. Ravaud,
None;

E. Maheu,
None;

G. Baron,
None;

A. Rialland,
None;

P. Vergnaud,
None;

C. Roux,
None;

Y. Maugars,
None;

D. Mulleman,
None;

B. Combe,
None;

D. Wendling,
None;

P. Laforgue,
None;

D. Loeuille,
None;

V. Foltz,
None;

P. Richette,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-multicentre-double-blind-placebo-controlled-trial-of-anti-tnf-alpha-adalimumab-in-refractory-hand-osteoarthritis-the-dora-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology